Pfizer wants the COVID vaccine for young children to be licensed in the US
Key Takeaways:
- As per a statement provided by the FDA on Monday, our pediatric COVID-19 vaccination advisory committee meetings have been rescheduled for June 14 and 15.
- According to the FDA, Moderna's emergency use authorization request for children aged six to seventeen will be discussed during the June 14 conference.
The US Food and Drug Administration has rescheduled its hearing for June 14-15 to consider Moderna Inc's COVID-19 vaccine for kids aged 6 months to 5 years and Pfizer Inc's vaccine for children aged 6 months to 4 years.
Our pediatric COVID-19 vaccine advisory group meetings have been rescheduled for June 14 and 15, as per the statement released by the FDA on Monday.
"We understand that parents are eager for us to evaluate whether or not these vaccines are safe and effective. We expect that, given Pfizer's disclosure of their data and anticipated submission dates, we will be able to finish examining both EUA petitions within days of each other, "Stated.
The FDA said the conference on June 14 would discuss Moderna's emergency use authorization request for children aged six to seventeen.
On Sunday, Dr. Ashish Jha, the White House COVID-19 response coordinator, said that he expects the US Food and Drug Administration to approve Moderna's vaccine for children under the age of five in the coming weeks.
According to Jha on ABC, Moderna has completed its application, and FDA experts are reviewing the data.
What are your concerns regarding Omicron?
CTVNews.ca needs to listen to Canadians with any questions about a new COVID-19 variation of concern known as Omicron.
Let us understand what you want to know about the Omicron COVID-19 version.
Send an email to dotcom@bellmedia.ca with your name, address, and question to ask a question. Your feedback may be used in a story on CTVNews.ca.